Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in Greece has been experiencing significant growth in recent years.
Customer preferences: One of the main reasons for this growth is the increasing demand for anti-fibrinolytic drugs in the country. This can be attributed to a number of factors, including the aging population, the rise in chronic diseases, and the growing awareness of the benefits of these drugs among healthcare professionals and patients. Additionally, the availability of a wide range of anti-fibrinolytic drugs in the market has also contributed to the growth of the industry.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Greece is the increasing use of these drugs in the treatment of bleeding disorders. This is due to the fact that these drugs are highly effective in preventing excessive bleeding and can be used in a variety of medical conditions, including trauma, surgery, and dental procedures. Another trend in the market is the growing popularity of generic drugs, which are more affordable than branded drugs and are becoming increasingly accessible to patients.
Local special circumstances: In Greece, the healthcare system is largely public, with the government providing healthcare services to the majority of the population. However, due to the ongoing economic crisis in the country, the government has been forced to implement austerity measures, which have resulted in cuts to healthcare spending. This has had a significant impact on the Anti-Fibrinolytic Drugs market, as patients are now more likely to opt for generic drugs, which are cheaper than branded drugs.
Underlying macroeconomic factors: Another factor that has contributed to the growth of the Anti-Fibrinolytic Drugs market in Greece is the country's aging population. As the population ages, the incidence of chronic diseases, such as cardiovascular disease, stroke, and cancer, increases. This has led to an increase in the demand for drugs that can effectively treat these conditions. Additionally, the rise in medical tourism in Greece has also contributed to the growth of the industry, as more patients from other countries are seeking medical treatment in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
